Treatment of chronic inflammatory diseases with biologic agents: Opportunities and risks for the elderly

Alejandro Diaz-Borjon, Cornelia M. Weyand, Jörg J. Goronzy

Research output: Contribution to journalShort surveypeer-review

6 Scopus citations

Abstract

The treatment armamentarium in rheumatic inflammatory diseases has drastically increased in the last years. Earlier uses of conventional disease-modifying antirheumatic drugs (DMARDs), along with the arrival of newer therapies including the so-called "biologic" agents, have provided better long-term outcomes for patients suffering from these illnesses. Biologic agents have shown efficacy for several diseases and failed in others. Due to a high prevalence of some of these diseases in the elderly population, this age group may also benefit, although treatment will have to be tailored to its special needs. In this mini review, we will discuss the use of these medications in rheumatic diseases with a significant prevalence in the elderly, their proven and potential uses, and the considerations that need to be taken into account when using them in this population.

Original languageEnglish (US)
Pages (from-to)1250-1255
Number of pages6
JournalExperimental Gerontology
Volume41
Issue number12
DOIs
StatePublished - Dec 2006

Keywords

  • Autoimmune rheumatic disease
  • B cells
  • Biologic agents
  • Elderly
  • T cells

ASJC Scopus subject areas

  • Biochemistry
  • Aging
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Cell Biology

Fingerprint Dive into the research topics of 'Treatment of chronic inflammatory diseases with biologic agents: Opportunities and risks for the elderly'. Together they form a unique fingerprint.

Cite this